Autologous Dendritic Cell Vaccination in Mesothelioma

Inclusion Criteria: * Diagnosis with histologically proven epithelial * Aged ≥ 18 years at the time of enrollment * WHO performance status 0-1 at the time of enrollment * Fit to undergo general anesthesia, a thoracoscopy, leukapheresis, chemotherapy, immunotherapy and P/D (in case of resectable disease) * No history of receiving any investigational treatment within 28 days of study enrollment * No history of intolerance to pemetrexed and/or cisplatin * Women of child bearing potential must have negative serum or urine pregnancy test at the time of screening. They should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least hundred days after the last study treatment. If pregnancy does occur within this time period, the Principal investigator must be informed as soon as possible. Female subjects who are breastfeeding should discontinue nursing prior to the first dose of study treatment and until hundred days after the last study treatment * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discusses with the patient before registration in the trial. Absence of any other inability or unwillingness to comply with the requirements of the protocol as assessed by the investigator * Before patient registration written informed consent must be given according to ICH/GCP, and national…